ArticleBiomedical reports2025
Serum soluble Tim‑3 is elevated in patients with cervical cancer and is higher in advanced clinical stages.
Article in Biomedical reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immune checkpoint TIM-3 in tumor immunotherapy.Acta biochimica et biophysica Sinica · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
T-cell immunoglobulin and mucin domain-containing protein-3 (Tim-3) is an immune checkpoint molecule that is expressed generally on the cell membrane of immune and cancer cells and is implicated as a negative regulator of anti-tumour immune responses; this occurs through the interaction of Tim-3 with galectin-9. Although the function of membrane Tim-3 is well known, the role of soluble Tim-3 (sTim-3) has been poorly explored. The aim of the present study was to compare the serum levels of sTim-3 in the cervical cancer group of patients vs. the control group, to determine the association between the serum levels of sTim-3 with the clinicopathological characteristics of patients with cervical cancer and with serum galectin-9 levels. The concentrations of serum sTim-3 and galectin-9 were determined using ELISA. A receiver operating characteristic (ROC) curve was performed to determine the diagnostic value of sTim-3. The Mann-Whitney and Kruskall-Wallis tests were used to compare the serum sTim-3 concentrations between the control and cervical cancer groups and among the clinical subgroups. The association between the concentrations of sTim-3 and galectin-9 was determined using Spearman's rank correlation coefficient. sTim-3 expression was higher in patients with cervical cancer compared with control patients. The ROC curve revealed that sTim-3 has diagnostic potential, with a specificity of 95% and a sensitivity of 85.19%. sTim-3 was higher in patients with International Federation of Gynaecology and Obstetrics (FIGO) stage IV compared with those with FIGO stages I, II and III. A moderate positive correlation (ρ=0.41) was identified between sTim-3 and galectin-9. This was the first report of changes in the serum concentrations of sTim-3 in patients with cervical cancer and their diagnostic value. The association between sTim-3 with cervical cancer progression, and the positive correlation between the serum concentrations of sTim-3 and galectin-9 suggested that both proteins might be involved in the immune dysregulation in cervical cancer, but this requires further exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.